Glucagon

DRUG INFORMATION

  ADULT
    - Recommended Dosage Recommended dose for adult and pediatric patients aged 12 years
      of age and older is 1 mg.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29
    - Recommended dose for adult and pediatric patients aged 12 years of age and older
      is 1 mg.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29
    - The recommended dose for pediatric patients aged 2 to less than 12 years of age
      who weigh: Less than 45 kg, is 0.5 mg 45 kg or greater, is 1 mg Dosage and
      Administration of GVOKE VialDx for Intravenous Use as a Diagnostic Aid in Adults (
      2.2 ) GVOKE VialDx is only for intravenous use under medical supervision.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Dosage and Administration of GVOKE for Subcutaneous Use to Treat Severe
      Hypoglycemia in Adult and Pediatric Patients Aged 2 Years and Older with Diabetes
      ( 2.1 ) Important Administration Instructions Administer GVOKE HypoPen, GVOKE PFS,
      or GVOKE Kit subcutaneously. These three presentations are referred to as GVOKE in
      this labeling Administer GVOKE according to the printed instructions on the foil
      pouch label, carton, or the Instructions for Use.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29
    - Recommended Dosage Recommended dose for adult and pediatric patients aged 12 years
      of age and older is 1 mg.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29
    - Recommended dose for adult and pediatric patients aged 12 years of age and older
      is 1 mg.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for glucagon (Gvoke VialDx),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for glucagon (Gvoke VialDx),
      retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Available data from case reports and a small number of observational
      studies with glucagon use in pregnant women over decades of use have not
      identified a drug-associated risk of major birth defects, miscarriage or adverse
      maternal or fetal outcomes.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'pregnancy', retrieved
      2026-08-29
    - Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon
      across the human placental barrier during early gestation.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'pregnancy', retrieved
      2026-08-29
    - In a rat reproduction study, no embryofetal toxicity was observed with glucagon
      administered by injection during the period of organogenesis at doses representing
      up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data) .
      Source: US FDA label for glucagon (Gvoke VialDx), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by
      injection at doses up to 2 mg/kg (up to 40 times the human dose based on body
      surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was
      no evidence of increased malformations or embryofetal lethality.
      Source: US FDA label for glucagon (Gvoke VialDx), section 'use in specific
      populations', retrieved 2026-08-29